Transparency and reporting characteristics of COVID-19 randomized controlled trials
Abstract Background In the context of the COVID-19 pandemic, randomized controlled trials (RCTs) are essential to support clinical decision-making. We aimed (1) to assess and compare the reporting characteristics of RCTs between preprints and peer-reviewed publications and (2) to assess whether repo...
Main Authors: | Philipp Kapp, Laura Esmail, Lina Ghosn, Philippe Ravaud, Isabelle Boutron |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12916-022-02567-y |
Similar Items
-
Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study
by: Brennan C. Kahan, et al.
Published: (2018-05-01) -
Influence of peer review on the reporting of primary outcome(s) and statistical analyses of randomised trials
by: Sally Hopewell, et al.
Published: (2018-01-01) -
Avoidable waste of research related to outcome planning and reporting in clinical trials
by: Youri Yordanov, et al.
Published: (2018-06-01) -
Assessment of transparency and selective reporting of interventional trials studying colorectal cancer
by: Anna Pellat, et al.
Published: (2022-03-01) -
Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events
by: Evan Mayo-Wilson, et al.
Published: (2019-09-01)